Since 2001 we encountered 4 women who experienced cerebral infarction during long-term hormone replacement therapy (HRT). 2,3 We pointed out in our articles that their cerebral infarcts were attributable to HRT-mediated changes in the coagulation system. The review of Bushnell et al 1 described that the precise mechanism of an estrogen-associated increase in risk for venous (as well as arterial) thrombotic events remains unknown despite accumulated evidences of hemostatic biomarkers change in a prothromboic direction. In our patients we observed depressed levels of protein C and S activity. Protein S activity returned to the normal range after cessation of HRT. 3 The HRT-induced procoagulant state might be attributable to an interaction among subtle changes in the coagulation system. Based on our published findings, we strongly suggest that the level of protein C and S activity be monitored in women on long-term HRT to prevent the occurrence of stroke.
In the article entitled "Stroke in Women During Long-Term Hormone Replacement Therapy Influencing Coagulation Systems" by Inoue et al 1 , one of the authors, Yukitake Ushio, is incorrectly spelled. The correct spelling is Yukitaka Ushio. The publisher regrets this error.
The corrected version can now be viewed online at http://stroke.ahajournals.org.
